About EVQLV
EVQLV is a company based in New York (United States) founded in 2019 by Brett Averso and Andrew Satz. EVQLV offers products and services including EVQLV Platform, Structure Prediction, De Novo Design, and mAb Humanization. EVQLV operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
Products & Services of EVQLV
EVQLV offers a comprehensive portfolio of products and services, including EVQLV Platform, Structure Prediction, De Novo Design, and mAb Humanization.
Generates diverse antibodies using computational methods.
Predicts protein structures for antibody engineering.
Creates new antibodies from computational models.
Humanizes monoclonal antibodies for drug use.
People of EVQLV
14 people are tracked at EVQLV (4 in leadership, 8 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Brett Averso | Co-Founder & CTO | Leadership |
Andrew Satz | Co-Founder & CEO | Leadership |
Richard Fox | Chief Scientific Officer | Leadership |
Ben Maida | Chief Commercial Officer | Leadership |
Roland Dunbrack | Advisor | Board & advisors |
Slater Victoroff | Advisor | Board & advisors |
Simeon Simeonov | Advisor | Board & advisors |
Boris Shor | Advisor | Board & advisors |
Ken Moch | Advisor | Board & advisors |
Ron Lennox | Advisor | Board & advisors |
Vikas Goyal | Advisor | Board & advisors |
Victor Greiff | Advisor | Board & advisors |
Alexander Sonneborn | Finance & Operations Lead | Team |
Sebastian Steiniger | Research Advisor | Team |
Complete people profiles for EVQLV
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of EVQLV
EVQLV operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| argenx.com | 2008 | Ghent, Belgium | $61.9M | 355 | Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| ventyxbio.com | 2018 | Encinitas, United States | $165.3M | 79 | Therapeutics for autoimmune diseases are developed by the company. | |
| cogentbio.com | 2014 | Cambridge, United States | $77M | 164 | Precision therapies for genetically defined diseases are developed. | |
| drenbio.com | 2019 | San Carlos, United States | $131M | – | Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases. | |
| autolus.com | 2015 | London, United Kingdom | $181.37M | 51 | Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. |
Detailed competitors of EVQLV
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of EVQLV
The website of EVQLV (evqlv.com) receives about 2K visits a month.
- Monthly visits2K
▲ 2.8% vs previous month
Latest news on Evqlv
Complete news archive for EVQLV
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to EVQLV
10 companies that operate in the same segment as EVQLV (Hematology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small activating RNA therapeutics are developed to restore gene function. | 2008 | London, England, United Kingdom | USD 460.41 M | USD 23.07 M | 37 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 442 M | – | 66 | |
Developer of therapeutics for the treatment of hematologic diseases | 2017 | Cambridge, Massachusetts, United States | USD 140 M | – | 84 | |
Gene therapy platform is developed for chronic disease treatments. | 2015 | Stevenage, Hertfordshire, United Kingdom | USD 273.69 M | USD 435.87 K | 152 | |
Novel anticoagulants for thrombosis treatment are developed. | 2019 | Cambridge, Massachusetts, United States | USD 250 M | – | 14 | |
Developer of therapies for treating hemochromatosis & beta thalassemia | 1989 | San Diego, California, United States | – | USD 75.72 M | 71 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Hematology products and solutions are provided for medical applications. | 1971 | Braintree, Massachusetts, United States | – | USD 1.33 B | 3,020 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about EVQLV
EVQLV was founded in 2019.
EVQLV is headquartered in New York, United States. It is registered at New York, New York, United States.
Andrew Satz is the current CEO of EVQLV. They have also founded this company.
EVQLV was founded in 2019 and is headquartered in New York, United States. AI-based immunotherapies are developed by the company for cancer and immune diseases. Pipeline products include a CD38 inhibitor targeted at hematologic malignancies, an ERBB2 inhibitor for gastroesophageal cancer, and an IL17A inhibitor for autoimmune diseases. Operations focus on biotechnology within the immunotherapy sector.
EVQLV's top competitors include Moderna, argenx and Forge Biologics.
EVQLV offers EVQLV Platform, Structure Prediction, De Novo Design, and mAb Humanization.
EVQLV operates through Evqlv Inc.